Page 1

01 02 03 04 INTERIM REPORT Q3 2021 | ACTIVE BIOTECH AB " We have seen the first encouraging results from the ongoing tasquinimod trial in multiple myeloma and started a new combination study with naptumomab and docetaxel in lung cancer " THIRD QUARTER IN BRIEF Active Biotech provided status update of its clinical naptumomab project on July 5 • Active Biotech's partner NeoTX hosted KOL webinar on overcoming checkpoint inhibitor resistance on July 8 ● EVENTS AFTER THE END OF THE PERIOD Tasquinimod clinical development in multiple myeloma advanced into combination therapy following completion of the initial phase of the ongoing trial in the US ( Oct 3 ) ● Active Biotech Active Active Biotech and NeoTX announced that the first patient had been enrolled in the phase lla clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non - small cell lung cancer ( NSCLC ) ( Oct 20 ) FINANCIAL SUMMARY SEK M Net sales Operating profit / loss Profit / loss after tax Earnings per share ( SEK ) Cash and cash equivalents ( at close of period ) 2021 The report is also available at www.activebiotech.com Jul - Sep -11.3 -11.2 -0.05 2020 -8.3 -8.2 -0.05 2021 Jan - Sep -33.6 -33.7 -0.16 68.4 2020 0.5 -28.2 -28.2 -0.17 30.9 Full Year 2020 6.7 -32.3 -32.2 -0.19 26.2 Active Biotech is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation . This information was provided to the media , through the agency of the contact persons set out above , for publication on November 4 , 2021 at 08.30 a.m. CET . Active Biotech AB ( Corp. reg . no . 556223-9227 ) / Scheelevägen 22 , SE - 223 63 Lund / +46 ( 0 ) 46 19 20 00 / www.activebiotech.com Helén Tuvesson , CEO : +46 ( 0 ) 46 19 21 56 / Hans Kolam , CFO : +46 ( 0 ) 46 19 20 44